2-propanol has been researched along with Glaucoma, Neovascular in 101 studies
2-Propanol: An isomer of 1-PROPANOL. It is a colorless liquid having disinfectant properties. It is used in the manufacture of acetone and its derivatives and as a solvent. Topically, it is used as an antiseptic.
propan-2-ol : A secondary alcohol that is propane in which one of the hydrogens attached to the central carbon is substituted by a hydroxy group.
Glaucoma, Neovascular: A form of secondary glaucoma which develops as a consequence of another ocular disease and is attributed to the forming of new vessels in the angle of the anterior chamber.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the outcomes of trabeculectomy with mitomycin C (MMC) combined with direct cauterization of peripheral iris before iridectomy in the management of neovascular glaucoma (NVG), and to demonstrate the effect of this surgical technique on decreasing the incidence of intraoperative bleeding and early postoperative hyphema." | 3.73 | Trabeculectomy with mitomycin C combined with direct cauterization of peripheral iris in the management of neovascular glaucoma. ( Batman, A; Berker, N; Cankaya, B; Elgin, U; Simsek, T, 2006) |
| "Intraocular pressure was significantly (P < 0." | 2.70 | Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. ( Hayler, JK; Jonas, JB; Panda-Jonas, S; Söfker, A, 2001) |
| "Neovascular glaucoma is a serious complication associated with retinal ischemic changes, which increase the production of vascular endothelial growth factor." | 2.52 | [Effect of Intravitreal Bevacizumab Injection on Iris and Iridocorneal Angle Neovascularization in Neovascular Glaucoma]. ( Ishibashi, S; Kondo, H, 2015) |
| "Neovascular glaucoma is defined as an iris and/or anterior chamber angle neovascularization associated with increased intraocular presure." | 2.48 | [Neovascular glaucoma--etipathogeny and diagnosis]. ( Călugăru, D; Călugăru, M, 2012) |
| "Neovascular glaucoma is a devastating ocular disease that often results in loss of vision." | 2.41 | Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. ( Gass, JD; O'Day, DM; Sivak-Callcott, JA; Tsai, JC, 2001) |
| "Right intraocular pressure was markedly increased, and corneal edema and increased iris neovascularization were also recognized." | 1.39 | Deterioration of glaucoma after carotid endarterectomy. ( Fujimoto, A; Katsuta, T; Oba, K, 2013) |
| "A pterygium is characterized, amongst others, by fibrovascular proliferation and may have vision threatening consequences if left untreated." | 1.36 | Antivascular endothelial growth factors in anterior segment diseases. ( Augustin, AJ; Kirchhof, J; Scholl, S, 2010) |
| "Neovascular glaucoma is a chronic and sight-threatening disease." | 1.34 | [OCT and neovascular glaucoma]. ( Baudouin, C; Bellotti, A; El Mahtoufi, A; Fayol, N; Labbé, A, 2007) |
| "However, 2 eyes showed a recurrence of neovascularization; in 1 case, it recurred after 3 months, and in the second, after 5 months." | 1.34 | Role of intravitreal bevacizumab in neovascular glaucoma. ( de Barros, DS; Garg, SJ; Gheith, ME; Moster, MR; Siam, GA, 2007) |
| "Neovascular glaucoma is a frequent complication of vitrectomy performed to treat proliferative diabetic retinopathy (PDR)." | 1.32 | Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy. ( Itakura, H; Kishi, S; Kotajima, N; Murakami, M, 2004) |
| "Neovascular glaucoma is a dreadful pathology with a rapid spontaneous evolution responsible for painful and blind eye." | 1.31 | [Consensus on neovascular glaucoma]. ( Baudouin, C; Hamard, P, 2000) |
| "We conclude that neovascular glaucoma is more likely to occur in older subjects with CRVO." | 1.29 | Are there medical conditions specifically underlying the development of rubeosis in central retinal vein occlusion? ( Dodson, PM; Keenan, JM; Kritzinger, EE, 1993) |
| "We report a case of central retinal vein occlusion presenting several capillary macroaneurysms." | 1.29 | Capillary macroaneurysms in central retinal vein occlusion. ( Battaglia Parodi, M; Bondel, E; Ravalico, G, 1995) |
| "The efficacy of treating diabetic neovascular glaucoma by panretinal cryotherapy and trabeculectomy was studied over post-operative periods of 6-24 months in 26 selected eyes (8 acute cases and 18 chronic cases)." | 1.27 | Treatment of diabetic neovascular glaucoma by panretinal ablation and trabeculectomy. ( Castro, J; Cordido, M; Fernández-Sabugal, J; Fernández-Vigo, J, 1988) |
| "A 32-year-old man with central retinal vein occlusion followed by severe and rapidly progressing neo-vascular glaucoma is presented." | 1.27 | Severe ischemic process in a young man with central retinal vein occlusion. ( Chen, V; Moisseiev, J; Treister, G, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (1.98) | 18.7374 |
| 1990's | 29 (28.71) | 18.2507 |
| 2000's | 39 (38.61) | 29.6817 |
| 2010's | 28 (27.72) | 24.3611 |
| 2020's | 3 (2.97) | 2.80 |
| Authors | Studies |
|---|---|
| Rallo-López, AJ | 1 |
| Orts-Llácer, J | 1 |
| Cauto-Picazo, C | 1 |
| Peñarrocha-Oltra, S | 1 |
| Martínez-Costa, R | 1 |
| Oxenreiter, MM | 1 |
| Lane, AM | 1 |
| Aronow, MB | 1 |
| Shih, H | 1 |
| Trofimov, AV | 1 |
| Kim, IK | 1 |
| Gragoudas, ES | 2 |
| Senthil, S | 1 |
| Dada, T | 1 |
| Das, T | 1 |
| Kaushik, S | 3 |
| Puthuran, GV | 1 |
| Philip, R | 1 |
| Rani, PK | 1 |
| Rao, H | 1 |
| Singla, S | 1 |
| Vijaya, L | 1 |
| Nakakura, S | 1 |
| Kobayashi, Y | 1 |
| Matsuya, K | 1 |
| Terao, E | 1 |
| Kiuchi, Y | 2 |
| Dong, Z | 1 |
| Gong, J | 1 |
| Liao, R | 1 |
| Xu, S | 1 |
| Toyama, S | 1 |
| Tsuji, H | 1 |
| Mizoguchi, N | 1 |
| Nomiya, T | 1 |
| Kamada, T | 1 |
| Tokumaru, S | 1 |
| Mizota, A | 1 |
| Ohnishi, Y | 1 |
| Tsujii, H | 1 |
| Călugăru, D | 1 |
| Călugăru, M | 1 |
| SooHoo, JR | 1 |
| Seibold, LK | 1 |
| Kahook, MY | 1 |
| Nadal, J | 1 |
| Carreras, E | 1 |
| Kudsieh, B | 1 |
| Canut, M | 1 |
| Katsuta, T | 1 |
| Fujimoto, A | 1 |
| Oba, K | 1 |
| Lüke, J | 1 |
| Nassar, K | 1 |
| Lüke, M | 1 |
| Grisanti, S | 2 |
| Waisbourd, M | 1 |
| Shemesh, G | 1 |
| Kurtz, S | 1 |
| Rachmiel, R | 1 |
| Moisseiev, E | 1 |
| Zayit-Soudri, S | 1 |
| Loewenstein, A | 1 |
| Barequet, I | 1 |
| Noma, H | 1 |
| Mimura, T | 1 |
| Yasuda, K | 1 |
| Shimura, M | 1 |
| Arcieri, ES | 1 |
| Paula, JS | 2 |
| Jorge, R | 3 |
| Barella, KA | 1 |
| Arcieri, RS | 1 |
| Secches, DJ | 1 |
| Costa, VP | 1 |
| Mantel, I | 1 |
| Schalenbourg, A | 2 |
| Bergin, C | 1 |
| Petrovic, A | 1 |
| Weber, DC | 1 |
| Zografos, L | 1 |
| Hou, XR | 1 |
| Miao, H | 1 |
| Tao, Y | 1 |
| Li, XX | 1 |
| Wong, IY | 1 |
| Ishibashi, S | 2 |
| Kondo, H | 1 |
| Kataria, P | 1 |
| Singh, SR | 1 |
| Pandav, SS | 2 |
| Coupland, S | 1 |
| Kacperek, A | 1 |
| Damato, B | 1 |
| Demidenko, A | 1 |
| Jakobiec, FA | 1 |
| Hanna, E | 1 |
| Walton, DS | 1 |
| Vásquez, LM | 1 |
| Somani, S | 1 |
| Altomare, F | 1 |
| Simpson, ER | 1 |
| Duch, S | 1 |
| Buchacra, O | 1 |
| Milla, E | 1 |
| Andreu, D | 1 |
| Tellez, J | 1 |
| Lupinacci, AP | 1 |
| Calzada, JI | 1 |
| Rafieetery, M | 1 |
| Charles, S | 1 |
| Netland, PA | 1 |
| Chen, CH | 1 |
| Lai, IC | 1 |
| Wu, PC | 1 |
| Chen, YJ | 1 |
| Chen, YH | 1 |
| Lee, JJ | 1 |
| Liu, YC | 1 |
| Kuo, HK | 1 |
| Yeung, SN | 1 |
| Paton, KE | 1 |
| Waite, C | 1 |
| Maberley, DA | 1 |
| Sugimoto, Y | 1 |
| Mochizuki, H | 1 |
| Okumichi, H | 1 |
| Takumida, M | 1 |
| Takamatsu, M | 1 |
| Kawamata, S | 1 |
| Scholl, S | 1 |
| Kirchhof, J | 1 |
| Augustin, AJ | 1 |
| Tawara, A | 1 |
| Sohma, R | 1 |
| Kubota, T | 1 |
| Toh, N | 1 |
| Shiba, T | 1 |
| Takahashi, M | 1 |
| Hori, Y | 1 |
| Saishin, Y | 1 |
| Sato, Y | 1 |
| Maeno, T | 1 |
| George, MK | 1 |
| Tsai, JC | 2 |
| Loewen, NA | 1 |
| Kotecha, A | 1 |
| Spratt, A | 1 |
| Ogunbowale, L | 1 |
| dell'Omo, R | 2 |
| Kulkarni, A | 2 |
| Bunce, C | 1 |
| Franks, WA | 2 |
| Chan, CK | 1 |
| Ip, MS | 1 |
| Vanveldhuisen, PC | 1 |
| Oden, NL | 1 |
| Scott, IU | 2 |
| Tolentino, MJ | 2 |
| Blodi, BA | 1 |
| Wolf, A | 1 |
| von Jagow, B | 1 |
| Ulbig, M | 1 |
| Haritoglou, C | 1 |
| Ribeiro, VR | 1 |
| Sampaio, RB | 1 |
| Mendonca, RJ | 1 |
| Haddad, A | 1 |
| Tedesco, AC | 1 |
| Coutinho-Netto, J | 1 |
| Haendchen, HA | 1 |
| Sasamoto, Y | 1 |
| Oshima, Y | 2 |
| Miki, A | 2 |
| Wakabayashi, T | 2 |
| Song, D | 1 |
| Matsushita, K | 1 |
| Hamasaki, T | 1 |
| Nishida, K | 1 |
| Joshi, L | 1 |
| Tomkins-Netzer, O | 1 |
| Menezo, V | 1 |
| Sallam, A | 1 |
| Kirkpatrick, N | 1 |
| Lightman, S | 1 |
| Taylor, SR | 1 |
| Hayreh, SS | 2 |
| Fuller, JJ | 1 |
| Mason, JO | 2 |
| White, MF | 1 |
| McGwin, G | 1 |
| Emond, TL | 1 |
| Feist, RM | 1 |
| Parodi, MB | 2 |
| Iacono, P | 1 |
| Itakura, H | 1 |
| Kishi, S | 1 |
| Kotajima, N | 1 |
| Murakami, M | 1 |
| Schäfer, S | 1 |
| Lang, GE | 1 |
| Davidorf, FH | 1 |
| Mouser, JG | 1 |
| Derick, RJ | 1 |
| Krzystolik, MG | 1 |
| Filippopoulos, T | 1 |
| Ducharme, JF | 1 |
| Loewenstein, JI | 1 |
| Biester, S | 1 |
| Peters, S | 1 |
| Tatar, O | 1 |
| Ziemssen, F | 1 |
| Bartz-Schmidt, KU | 1 |
| Valković, A | 1 |
| Kovacević, D | 1 |
| Valković Antić, I | 1 |
| Silva Paula, J | 1 |
| Alves Costa, R | 1 |
| Rodrigues, Mde L | 1 |
| Shields, CL | 2 |
| Sun, H | 1 |
| Manquez, ME | 1 |
| Leahey, A | 1 |
| Meadows, AT | 1 |
| Shields, JA | 2 |
| Albert, MA | 1 |
| Mays, A | 1 |
| Vail, R | 1 |
| Elgin, U | 1 |
| Berker, N | 1 |
| Batman, A | 1 |
| Simsek, T | 1 |
| Cankaya, B | 1 |
| Telander, DG | 1 |
| Holland, GN | 1 |
| Wax, MB | 1 |
| Van Gelder, RN | 1 |
| Löffler, KU | 1 |
| Iliev, ME | 1 |
| Domig, D | 1 |
| Wolf-Schnurrbursch, U | 1 |
| Wolf, S | 1 |
| Sarra, GM | 1 |
| Madhusudhana, KC | 1 |
| Newsom, RS | 1 |
| Mennel, S | 1 |
| Barbazetto, I | 1 |
| Meyer, CH | 1 |
| Peter, S | 1 |
| Stur, M | 1 |
| Batioğlu, F | 1 |
| Astam, N | 1 |
| Ozmert, E | 1 |
| Bellotti, A | 1 |
| Labbé, A | 1 |
| Fayol, N | 1 |
| El Mahtoufi, A | 1 |
| Baudouin, C | 2 |
| Chilov, MN | 1 |
| Grigg, JR | 1 |
| Playfair, TJ | 1 |
| Gheith, ME | 1 |
| Siam, GA | 1 |
| de Barros, DS | 1 |
| Garg, SJ | 1 |
| Moster, MR | 1 |
| Ichhpujani, P | 1 |
| Ramasubramanian, A | 1 |
| Cheng, JY | 1 |
| Wong, DW | 1 |
| Ang, CL | 1 |
| Sakaguchi, H | 1 |
| Ikuno, Y | 1 |
| Gomi, F | 1 |
| Otori, Y | 1 |
| Kamei, M | 1 |
| Kusaka, S | 1 |
| Tano, Y | 1 |
| Sandramouli, S | 2 |
| Sihota, R | 2 |
| Sood, NN | 2 |
| Stirpe, M | 1 |
| Bucci, MG | 1 |
| Quaranta, L | 1 |
| Stefaniotou, M | 1 |
| Paschides, CA | 1 |
| Psilas, K | 1 |
| Blinder, KJ | 1 |
| Friedman, SM | 1 |
| Mames, RN | 1 |
| Keenan, JM | 1 |
| Dodson, PM | 1 |
| Kritzinger, EE | 1 |
| Battaglia Parodi, M | 1 |
| Bondel, E | 2 |
| Ravalico, G | 2 |
| Miller, JW | 1 |
| Chatzistefanou, K | 1 |
| Ferrara, N | 1 |
| Adamis, AP | 2 |
| van Meurs, JC | 1 |
| Bolt, BJ | 1 |
| Mertens, DA | 1 |
| Peperkamp, E | 1 |
| De Waard, P | 1 |
| Fernández-Vigo, J | 2 |
| Castro, J | 2 |
| Macarro, A | 1 |
| Bourke, RD | 1 |
| Cooling, RJ | 1 |
| Tripathi, RC | 1 |
| Li, J | 1 |
| Tripathi, BJ | 1 |
| Chalam, KV | 1 |
| Browning, DJ | 1 |
| Scott, AQ | 1 |
| Peterson, CB | 1 |
| Warnock, J | 1 |
| Zhang, Z | 1 |
| Luttrull, JK | 1 |
| Avery, RL | 1 |
| Chen, PP | 1 |
| Kalina, RE | 1 |
| Helbig, H | 1 |
| Kellner, U | 1 |
| Bornfeld, N | 1 |
| Foerster, MH | 1 |
| Höche, A | 1 |
| Blum, M | 1 |
| Semeniuk, C | 1 |
| Lorenz, P | 1 |
| Kosmehl, H | 1 |
| Strobel, J | 1 |
| Terasaki, H | 1 |
| Miyake, Y | 1 |
| Mori, M | 1 |
| Suzuki, T | 1 |
| Kondo, M | 1 |
| Chen, KH | 1 |
| Wu, CC | 1 |
| Roy, S | 1 |
| Lee, SM | 1 |
| Liu, JH | 1 |
| Ando, A | 1 |
| Takahashi, K | 1 |
| Sho, K | 1 |
| Matsushima, M | 1 |
| Okamura, A | 1 |
| Uyama, M | 1 |
| Hamard, P | 1 |
| Saviano, S | 1 |
| Salmon, JF | 1 |
| Ursell, PG | 1 |
| Frith, P | 1 |
| Jonas, JB | 1 |
| Hayler, JK | 1 |
| Söfker, A | 1 |
| Panda-Jonas, S | 1 |
| Sivak-Callcott, JA | 1 |
| O'Day, DM | 1 |
| Gass, JD | 1 |
| Hamanaka, T | 1 |
| Akabane, N | 1 |
| Yajima, T | 1 |
| Takahashi, T | 1 |
| Tanabe, A | 1 |
| Chao, AN | 1 |
| Krema, H | 1 |
| Rehák, J | 2 |
| Lam, S | 1 |
| Tessler, HH | 1 |
| Lam, BL | 1 |
| Wilensky, JT | 1 |
| Brooks, AM | 1 |
| Gillies, WE | 1 |
| Klugman, MR | 1 |
| Podhajsky, P | 1 |
| Servais, GE | 1 |
| Perkins, ES | 1 |
| Duker, JS | 1 |
| Sivalingam, A | 1 |
| Brown, GC | 1 |
| Reber, R | 1 |
| Hennis, HL | 1 |
| Stewart, WC | 1 |
| Fiore, PM | 1 |
| Latina, MA | 1 |
| Shingleton, BJ | 1 |
| Rizzo, JF | 1 |
| Ebert, E | 1 |
| Bellows, AR | 1 |
| Cordido, M | 1 |
| Fernández-Sabugal, J | 1 |
| Chen, V | 1 |
| Moisseiev, J | 1 |
| Treister, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT02647515] | Phase 4 | 18 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| An Open Label, Prospective, Monocenter, Prove of Concept Study to Evaluate the Short- and Long-term Effects of 0.5mg Intraocular Ranibizumab (Lucentis) Injections as Adjuvant for Patients With Rubeosis and Neovascular Glaucoma[NCT01370135] | 20 participants (Actual) | Interventional | 2008-11-30 | Completed | |||
| The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide With Standard Care to Treat Macular Edema[NCT00105027] | Phase 3 | 682 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage V.[NCT00500396] | Phase 4 | 15 participants (Anticipated) | Interventional | 2007-03-31 | Completed | ||
| Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous and Subretinal Fluid in Patients With Retinopathy of Prematurity Stage IV and V[NCT00563121] | Phase 4 | 16 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Randomized Controlled Trial of Lucentis in the Management of New Onset Neovascular Glaucoma[NCT00727038] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2008-01-04 | Withdrawn (stopped due to Company withdrew funding/sponsorship) | ||
| Vascular Endothelial Growth Factor (VEGF)Blockade With Intravitreal Pegaptnib in Non-Infectious Uveitic Cystoid Macular Edema (CME)[NCT00790803] | 5 participants (Actual) | Interventional | 2009-03-31 | Completed | |||
| Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment[NCT00548197] | Phase 1 | 40 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Subconjunctival Bevacizumab Injection for the Prevention of Bleb Vascularization Post Trabeculectomy[NCT00854529] | Phase 2 | 60 participants (Anticipated) | Interventional | 2009-04-30 | Not yet recruiting | ||
| Uncovering Inflammatory Mediators of Glaucoma Pathogenesis After Corneal Transplantation in Aqueous Humor and Tears[NCT04339907] | 200 participants (Anticipated) | Interventional | 2020-05-11 | Recruiting | |||
| Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection[NCT00491712] | 49 participants (Actual) | Interventional | 2005-09-30 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00105027)
Timeframe: 12 months
| Intervention | letters read (Mean) |
|---|---|
| CRVO Observation | -12.1 |
| CRVO 1 mg Dose Triamcinolone Acetonide | -1.2 |
| CRVO 4 mg Dose Triamcinolone Acetonide | -1.2 |
| BRVO Standard Care | 4.2 |
| BRVO 1 mg Dose Triamcinolone Acetonide | 5.7 |
| BRVO 4 mg Dose Triamcinolone Acetonide | 4.0 |
(NCT00105027)
Timeframe: 12 months
| Intervention | um (Median) |
|---|---|
| CRVO Observation | -277 |
| CRVO 1 mg Dose Triamcinolone Acetonide | -196 |
| CRVO 4 mg Dose Triamcinolone Acetonide | -261 |
| BRVO Standard Care | -224 |
| BRVO 1 mg Dose Triamcinolone Acetonide | -149 |
| BRVO 4 mg Dose Triamcinolone Acetonide | -170 |
Visual acuity testing was done using electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity testing at 3 meters using the Electronic Visual Acuity Tester by a SCORE certified technician. A masked visual acuity examiner with no knowledge of treatment assignments performed visual acuity testing at the 4-month, 12-month, 24-month and 36-month visits. An E-ETDRS visual acuity score of 85 is approximately 20/20, and a score of 20 letters is approximately 20/400. A visual acuity letter score change of 15 is about three lines on a vision chart. (NCT00105027)
Timeframe: Change from baseline to 12 months
| Intervention | Participants (Number) |
|---|---|
| CRVO Observation | 5 |
| CRVO 1 mg Dose Triamcinolone Acetonide | 22 |
| CRVO 4 mg Dose Triamcinolone Acetonide | 21 |
| BRVO Standard Care | 35 |
| BRVO 1 mg Dose Triamcinolone Acetonide | 31 |
| BRVO 4 mg Dose Triamcinolone Acetonide | 34 |
(NCT00105027)
Timeframe: 12 months
| Intervention | events (Number) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Initiation of IOP-lowering medications | IOP > 35 mm HG | IOP > 10 mm HG above baseline | Laser peripheral iridotomy | Trabeculectomy | Tube shunt | Cataract: lens opacity onset or progression | Cataract surgery | Infectious endophthalmitis | Noninfectious endophthalmitis | Retinal detachment | Iris neovascularization | Retinal neovascularization | Vitreous hemorrhage | YAG capsulotomy | Sector or panretinal photocagulation | Pars plana vitrectomy | |
| BRVO 1 mg Dose Triamcinolone Acetonide | 11 | 2 | 12 | 0 | 0 | 0 | 27 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 |
| BRVO 4 mg Dose Triamcinolone Acetonide | 57 | 14 | 50 | 1 | 0 | 0 | 38 | 4 | 1 | 0 | 0 | 2 | 3 | 3 | 1 | 4 | 1 |
| BRVO Standard Care | 3 | 1 | 1 | 0 | 0 | 0 | 15 | 3 | 0 | 0 | 1 | 1 | 5 | 2 | 1 | 5 | 1 |
| CRVO 1 mg Dose Triamcinolone Acetonide | 18 | 5 | 15 | 0 | 0 | 2 | 20 | 0 | 0 | 0 | 0 | 9 | 2 | 4 | 0 | 9 | 2 |
| CRVO 4 mg Dose Triamcinolone Acetonide | 32 | 8 | 24 | 1 | 0 | 0 | 25 | 4 | 0 | 0 | 0 | 4 | 2 | 0 | 0 | 3 | 0 |
| CRVO Observation | 7 | 1 | 2 | 0 | 0 | 0 | 12 | 0 | 0 | 0 | 0 | 2 | 4 | 4 | 1 | 5 | 1 |
"The degree of cell and flare was recorded at each visit during the course of the trial in the injected eye.~In uveitis, severely inflamed vessels leak protein which clouds the normally clear aqueous. This looks hazy with the slit lamp. If severe, it disperses the light beam, causing flare.~White or red blood cells may be observed: the presence of inflammatory cells in the anterior chamber suggests inflammation of the iris and ciliary body.~Blood cells: grading of blood cells in the anterior chamber is as follows:~0 - None.~1+ - faint (barely detectable).~2+ - moderate (clear iris and lens details).~3+ - moderate (hazy iris and lens details).~4+ - intense (fibrin deposits, coagulated aqueous)." (NCT00790803)
Timeframe: 32 weeks
| Intervention | participants (Number) |
|---|---|
| Macugen | 0 |
No changes were to be made in immunodulatory medications of the patients unless needed for safety after in initiation of Macugen therapy. (NCT00790803)
Timeframe: 32 weeks
| Intervention | participants (Number) |
|---|---|
| Macugen | 0 |
Patients retinal thickness was measured at each visit bu imaging to monitor increase or decrease in thickness. (NCT00790803)
Timeframe: 32 weeks
| Intervention | participants (Number) |
|---|---|
| Macugen | 2 |
The primary outcome was an improvement in VA greater than or equal to fifteen letters on the EDTRS chart. (NCT00790803)
Timeframe: 32 weeks
| Intervention | participants (Number) |
|---|---|
| Macugen | 1 |
Patients best corrected visual acuity was measured at each visit to monitor gain or loss of letters on the EDTRS chart. (NCT00790803)
Timeframe: 32 weeks
| Intervention | paticipants (Number) |
|---|---|
| Macugen | 5 |
Number of Participants with Postoperative Vitreous Hemorrhage (NCT00548197)
Timeframe: Last follow up, an average of 7 months post-operation
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Group | 0 |
| Control Group | 7 |
Post operative best corrected visual acuity ( best distance vision with eyeglasses or contact lenses) (NCT00548197)
Timeframe: last follow up, an average of 7 months post-operation
| Intervention | LogMar (Mean) |
|---|---|
| Intervention | 1.1 |
| Control | 1.4 |
8 reviews available for 2-propanol and Glaucoma, Neovascular
| Article | Year |
|---|---|
Neovascular glaucoma - A review.
Topics: Diabetic Retinopathy; Glaucoma, Neovascular; Humans; Intraocular Pressure; Iris; Retinal Diseases; R | 2021 |
Effectiveness of multiple therapeutic strategies in neovascular glaucoma patients: A PRISMA-compliant network meta-analysis.
Topics: Angiogenesis Inhibitors; Anti-Infective Agents; Bevacizumab; Combined Modality Therapy; Glaucoma, Ne | 2018 |
[Neovascular glaucoma--etipathogeny and diagnosis].
Topics: Arterial Occlusive Diseases; Diabetic Retinopathy; Diagnosis, Differential; Eye; Eye Neoplasms; Glau | 2012 |
Recent advances in the management of neovascular glaucoma.
Topics: Angiogenesis Inhibitors; Filtering Surgery; Glaucoma, Neovascular; Humans; Iris; Laser Therapy; Neov | 2013 |
[Effect of Intravitreal Bevacizumab Injection on Iris and Iridocorneal Angle Neovascularization in Neovascular Glaucoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Bevacizumab; Capillary Permeability; Cornea; Glauco | 2015 |
Ocular photodynamic therapy--standard applications and new indications (part 1). Review of the literature and personal experience.
Topics: Choroidal Neovascularization; Clinical Trials as Topic; Glaucoma, Neovascular; Humans; Iris; Neovasc | 2007 |
Bevacizumab in glaucoma: a review.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Fil | 2007 |
Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma.
Topics: Antimetabolites; Evidence-Based Medicine; Fluorophotometry; Glaucoma Drainage Implants; Glaucoma, Ne | 2001 |
Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma.
Topics: Antimetabolites; Evidence-Based Medicine; Fluorophotometry; Glaucoma Drainage Implants; Glaucoma, Ne | 2001 |
Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma.
Topics: Antimetabolites; Evidence-Based Medicine; Fluorophotometry; Glaucoma Drainage Implants; Glaucoma, Ne | 2001 |
Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma.
Topics: Antimetabolites; Evidence-Based Medicine; Fluorophotometry; Glaucoma Drainage Implants; Glaucoma, Ne | 2001 |
6 trials available for 2-propanol and Glaucoma, Neovascular
| Article | Year |
|---|---|
Topical bevacizumab for neovascular glaucoma: a pilot study.
Topics: Administration, Ophthalmic; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal | 2014 |
Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing Ahmed glaucoma valve implantation: 2-year follow-up.
Topics: Angiogenesis Inhibitors; Anterior Chamber; Antibodies, Monoclonal, Humanized; Bevacizumab; Female; F | 2015 |
SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion.
Topics: Aged; Capillaries; Female; Glaucoma, Neovascular; Glucocorticoids; Humans; Incidence; Iris; Ischemia | 2011 |
Central vein occlusion study of photocoagulation therapy. Baseline findings. Central Vein Occlusion Study Group.
Topics: Adult; Aged; Aged, 80 and over; Female; Glaucoma, Neovascular; Humans; Iris; Ischemia; Laser Coagula | 1993 |
Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone.
Topics: Aged; Aged, 80 and over; Crystallization; Diabetic Retinopathy; Female; Glaucoma, Neovascular; Gluco | 2001 |
Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion. A 10-year prospective study.
Topics: Aged; Analysis of Variance; Clinical Protocols; Data Interpretation, Statistical; Female; Glaucoma, | 1990 |
87 other studies available for 2-propanol and Glaucoma, Neovascular
| Article | Year |
|---|---|
Neovascular glaucoma caused by small-cell lung cancer iris metastasis: A case presentation.
Topics: Glaucoma; Glaucoma, Neovascular; Humans; Intraocular Pressure; Iris; Lung Neoplasms; Vision Disorder | 2023 |
Proton beam irradiation of uveal melanoma involving the iris, ciliary body and anterior choroid without surgical localisation (light field).
Topics: Choroid; Ciliary Body; Follow-Up Studies; Glaucoma, Neovascular; Humans; Iris; Melanoma; Neoplasm Re | 2022 |
Iris Thickness and Severity of Neovascular Glaucoma Determined Using Swept-Source Anterior-segment Optical Coherence Tomography.
Topics: Adult; Aged; Aged, 80 and over; Anterior Capsule of the Lens; Case-Control Studies; Female; Glaucoma | 2018 |
Long-term results of carbon ion radiation therapy for locally advanced or unfavorably located choroidal melanoma: usefulness of CT-based 2-port orthogonal therapy for reducing the incidence of neovascular glaucoma.
Topics: Adult; Aged; Aged, 80 and over; Choroid Neoplasms; Ciliary Body; Female; Glaucoma, Neovascular; Heav | 2013 |
Neovascular glaucoma treatment with extraction of anterior chamber fibrovascular tissue.
Topics: Angiogenesis Inhibitors; Anterior Chamber; Antibodies, Monoclonal, Humanized; Bevacizumab; Fibrosis; | 2013 |
Deterioration of glaucoma after carotid endarterectomy.
Topics: Blindness; Corneal Edema; Diabetic Retinopathy; Disease Progression; Endarterectomy, Carotid; Eye; G | 2013 |
Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma--results from a prospective interventional case series.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antihype | 2013 |
Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma--results from a prospective interventional case series.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antihype | 2013 |
Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma--results from a prospective interventional case series.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antihype | 2013 |
Ranibizumab as adjuvant in the treatment of rubeosis iridis and neovascular glaucoma--results from a prospective interventional case series.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antihype | 2013 |
Vascular endothelial growth factor and its soluble receptors-1 and -2 in iris neovascularization and neovascular glaucoma.
Topics: Diabetic Retinopathy; Enzyme-Linked Immunosorbent Assay; Female; Glaucoma, Neovascular; Humans; Intr | 2014 |
Prophylactic use of bevacizumab to avoid anterior segment neovascularization following proton therapy for uveal melanoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Coloring Agent | 2014 |
Expression of cytokines on the iris of patients with neovascular glaucoma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Cytokines; Diabetic | 2015 |
A Novel Technique of a Transcorneal Suture to Manage an Iris Tuck into the Tube of a Glaucoma Drainage Device.
Topics: Adult; Cornea; Foreign-Body Migration; Glaucoma Drainage Implants; Glaucoma, Neovascular; Humans; In | 2016 |
Iridocyclectomy for neovascular glaucoma caused by proton-beam radiotherapy of pigmented ciliary adenocarcinoma.
Topics: Adenocarcinoma; Aged; Ciliary Body; Glaucoma, Neovascular; Humans; Intraocular Pressure; Iridectomy; | 2008 |
Congenital pupillary-iris-lens membrane with goniodysgenesis: a rare cause of glaucoma and vision loss.
Topics: Anterior Eye Segment; Blindness; Child; Eye Abnormalities; Eye Enucleation; Glaucoma, Neovascular; H | 2009 |
Intracameral bevacizumab in the treatment of neovascular glaucoma and exudative retinal detachment after brachytherapy in choroidal melanoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Bra | 2009 |
Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anterior Chamber; Antibodies, Monoclonal; A | 2009 |
Clinical outcomes of patients with anterior segment neovascularization treated with or without intraocular bevacizumab.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angiogenesis Inhibitors; Antibodies, Monoclonal; Anti | 2009 |
Adjunctive intravitreal bevacizumab-combined trabeculectomy versus trabeculectomy alone in the treatment of neovascular glaucoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Chemotherapy, A | 2010 |
Intravitreal bevacizumab for iris neovascularization following proton beam irradiation for choroidal melanoma.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizuma | 2010 |
Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2010 |
Antivascular endothelial growth factors in anterior segment diseases.
Topics: Administration, Topical; Angiogenesis Inhibitors; Anterior Eye Segment; Antibodies, Monoclonal; Anti | 2010 |
Angiographic changes in iris and iridocorneal angle neovascularization after intravitreal bevacizumab injection.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bev | 2010 |
Relationship between sleep-disordered breathing and iris and/or angle neovascularization in proliferative diabetic retinopathy cases.
Topics: Aged; Anterior Chamber; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fe | 2011 |
Bilateral irreversible severe vision loss from cosmetic iris implants.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Blindness; Device Rem | 2011 |
Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo | 2011 |
Intracameral injection of bevacizumab for the treatment of neovascular glaucoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anterior Chamber; Antibodies, Monoclonal; A | 2011 |
Rabbit rubeosis iridis induced by intravitreal latex-derived angiogenic fraction.
Topics: Angiogenesis Inducing Agents; Animals; Disease Models, Animal; Disease Progression; Drug Carriers; F | 2011 |
Clinical outcomes and changes in aqueous vascular endothelial growth factor levels after intravitreal bevacizumab for iris neovascularization and neovascular glaucoma: a retrospective two-dose comparative study.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aqueous Humor; | 2012 |
Dexamethasone implants and neovascular glaucoma in central retinal vein occlusion.
Topics: Dexamethasone; Drug Implants; Fluorescein Angiography; Glaucoma, Neovascular; Glucocorticoids; Gonio | 2013 |
Evidence-based recommendations for neovascular glaucoma.
Topics: Evidence-Based Medicine; Glaucoma, Neovascular; Humans; Iris; Laser Coagulation; Practice Guidelines | 2003 |
Retinochoroidal collateral veins protect against anterior segment neovascularization after central retinal vein occlusion.
Topics: Aged; Aged, 80 and over; Anterior Eye Segment; Choroid; Collateral Circulation; Female; Fluorescein | 2003 |
Photodynamic therapy with verteporfin for anterior segment neovascularizations in neovascular glaucoma.
Topics: Adult; Aged; Aged, 80 and over; Anterior Eye Segment; Fluorescein Angiography; Glaucoma, Neovascular | 2004 |
Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy.
Topics: Adult; Aged; Diabetic Retinopathy; Enzyme-Linked Immunosorbent Assay; Female; Glaucoma, Neovascular; | 2004 |
Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy.
Topics: Adult; Aged; Diabetic Retinopathy; Enzyme-Linked Immunosorbent Assay; Female; Glaucoma, Neovascular; | 2004 |
Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy.
Topics: Adult; Aged; Diabetic Retinopathy; Enzyme-Linked Immunosorbent Assay; Female; Glaucoma, Neovascular; | 2004 |
Persistent secretion of vascular endothelial growth factor into the vitreous cavity in proliferative diabetic retinopathy after vitrectomy.
Topics: Adult; Aged; Diabetic Retinopathy; Enzyme-Linked Immunosorbent Assay; Female; Glaucoma, Neovascular; | 2004 |
[Iris neovascularization as a complication of central artery occlusion].
Topics: Comorbidity; Cross-Sectional Studies; Follow-Up Studies; Glaucoma, Angle-Closure; Glaucoma, Neovascu | 2005 |
Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Choroid Neoplasms; Fluoresce | 2006 |
Pegaptanib as an adjunctive treatment for complicated neovascular diabetic retinopathy.
Topics: Aptamers, Nucleotide; Chemotherapy, Adjuvant; Diabetic Retinopathy; Glaucoma Drainage Implants; Glau | 2006 |
Intracameral bevacizumab for iris rubeosis.
Topics: Aged; Angiogenesis Inhibitors; Anterior Chamber; Antibodies, Monoclonal; Antibodies, Monoclonal, Hum | 2006 |
[Argon laser iridotomy in neovascular glaucoma].
Topics: Glaucoma, Angle-Closure; Glaucoma, Neovascular; Humans; Iris; Laser Therapy; Ophthalmologic Surgical | 2006 |
Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma.
Topics: Aged; Anterior Eye Segment; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; | 2006 |
Resolution of iris neovascularization following chemoreduction of advanced retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Fluorescein Angiogra | 2006 |
Regression of neovascular iris vessels by intravitreal injection of bevacizumab.
Topics: Aged; Angiogenesis Inhibitors; Anterior Eye Segment; Antibodies, Monoclonal; Antibodies, Monoclonal, | 2006 |
Trabeculectomy with mitomycin C combined with direct cauterization of peripheral iris in the management of neovascular glaucoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Cautery; Combined Modality Therapy; Female; Glaucoma, Neov | 2006 |
Rubeosis and anterior segment ischemia associated with systemic cryoglobulinemia.
Topics: Adult; Anterior Eye Segment; Atrophy; Cryoglobulinemia; Glaucoma, Neovascular; Humans; Iris; Ischemi | 2006 |
[Neovascular glaucoma: aetiology, pathogenesis and treatment].
Topics: Capillaries; Diabetic Retinopathy; Diagnosis, Differential; Eye Neoplasms; Glaucoma, Neovascular; Hu | 2006 |
Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu | 2006 |
Central retinal vein occlusion: the therapeutic options.
Topics: Combined Modality Therapy; Fluorescein Angiography; Glaucoma, Neovascular; Humans; Iris; Macular Ede | 2007 |
Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Flu | 2008 |
[OCT and neovascular glaucoma].
Topics: Anterior Eye Segment; Case Management; Diabetic Retinopathy; Female; Glaucoma, Neovascular; Humans; | 2007 |
Bevacizumab (Avastin) for the treatment of neovascular glaucoma.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2007 |
Role of intravitreal bevacizumab in neovascular glaucoma.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2007 |
Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurity.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizum | 2008 |
Intraocular avastin (bevacizumab) for neovascularisation of the iris and neovascular glaucoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bev | 2008 |
Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bev | 2008 |
Role of anterior retinal cryoablation in the management of neovascular glaucoma.
Topics: Adolescent; Adult; Aged; Cryosurgery; Female; Fluorescein Angiography; Follow-Up Studies; Glaucoma, | 1993 |
Central vein occlusion study of photocoagulation. Manual of operations. Central Vein Occlusion Study Group.
Topics: Adult; Clinical Protocols; Glaucoma, Neovascular; Humans; Iris; Ischemia; Laser Coagulation; Macular | 1993 |
Surgical avulsion of the iris to treat selected cases of neovascular glaucoma.
Topics: Adult; Cataract; Cell Membrane; Diabetic Retinopathy; Female; Follow-Up Studies; Glaucoma, Neovascul | 1994 |
Panretinal cryopexy for the management of neovascularization of the iris.
Topics: Aged; Cryosurgery; Diabetic Retinopathy; Female; Glaucoma, Neovascular; Humans; Iris; Iris Diseases; | 1995 |
Diabetic iris neovascularization.
Topics: Diabetes Complications; Female; Glaucoma, Neovascular; Gonioscopy; Humans; Iris; Laser Coagulation; | 1995 |
Are there medical conditions specifically underlying the development of rubeosis in central retinal vein occlusion?
Topics: Adult; Age Factors; Aged; Cardiovascular Diseases; Diabetes Complications; Female; Glaucoma, Neovasc | 1993 |
Capillary macroaneurysms in central retinal vein occlusion.
Topics: Aged; Aneurysm; Capillaries; Female; Fluorescein Angiography; Fundus Oculi; Glaucoma, Neovascular; H | 1995 |
Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate.
Topics: Animals; Capillary Permeability; Dose-Response Relationship, Drug; Endothelial Growth Factors; Fluor | 1996 |
Rubeosis of the iris in proliferative vitreoretinopathy.
Topics: Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Glaucoma, Neovascular; Humans; Iris; Light | 1996 |
Diabetic iris neovascularization. Natural history and treatment.
Topics: Cryotherapy; Diabetes Complications; Disease Progression; Female; Follow-Up Studies; Glaucoma, Neova | 1997 |
Case of rubeosis in association with proliferative vitreoretinopathy (PVR)
Topics: Fluorescein Angiography; Fundus Oculi; Glaucoma, Neovascular; Humans; Iris; Laser Coagulation; Neova | 1997 |
Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma.
Topics: Aged; Aged, 80 and over; Aqueous Humor; Cataract; Endothelial Growth Factors; Enzyme-Linked Immunoso | 1998 |
The risk of missing angle neovascularization by omitting screening gonioscopy in acute central retinal vein occlusion.
Topics: Acute Disease; Adult; Aged; Anterior Eye Segment; Female; Follow-Up Studies; Glaucoma, Neovascular; | 1998 |
Peripheral transscleral retinal diode laser for rubeosis iridis.
Topics: Glaucoma, Neovascular; Humans; Iris; Laser Therapy; Neovascularization, Pathologic; Sclera | 1998 |
Chronic angle-closure mimicking rubeotic glaucoma in an adult with retinopathy of prematurity.
Topics: Adult; Chronic Disease; Diagnosis, Differential; Glaucoma, Angle-Closure; Glaucoma, Neovascular; Hum | 1998 |
Rubeosis iridis after vitrectomy for diabetic retinopathy.
Topics: Adult; Aged; Aged, 80 and over; Diabetic Retinopathy; Female; Glaucoma, Neovascular; Humans; Inciden | 1998 |
[Secondary glaucoma caused by iris tumor. Iris metastasis of adenocarcinoma of the breast].
Topics: Adenocarcinoma; Breast Neoplasms; Diagnosis, Differential; Female; Glaucoma, Neovascular; Humans; Ir | 1999 |
Fluorescein angiography of extreme peripheral retina and rubeosis iridis in proliferative diabetic retinopathy.
Topics: Adult; Aged; Aged, 80 and over; Diabetic Retinopathy; Female; Fluorescein Angiography; Fundus Oculi; | 1999 |
Increased interleukin-6 in aqueous humor of neovascular glaucoma.
Topics: Aged; Aqueous Humor; Enzyme-Linked Immunosorbent Assay; Female; Glaucoma, Neovascular; Humans; Inter | 1999 |
Histopathological findings of X-linked retinoschisis with neovascular glaucoma.
Topics: Adult; Electroretinography; Eye Enucleation; Fluorescein Angiography; Fundus Oculi; Genetic Linkage; | 2000 |
[Consensus on neovascular glaucoma].
Topics: Adult; Age Factors; Aged; Diabetic Retinopathy; Electroretinography; Glaucoma, Neovascular; Humans; | 2000 |
Iris indocyanine green angiography in pseudoexfoliation syndrome and capsular glaucoma.
Topics: Aged; Aged, 80 and over; Capillary Permeability; Diagnosis, Differential; Exfoliation Syndrome; Fema | 2000 |
Neovascular glaucoma as a complication of retinal vasculitis in Crohn disease.
Topics: Administration, Topical; Anti-Inflammatory Agents; Crohn Disease; Fluorescein Angiography; Fundus Oc | 2000 |
Retinal ischemia and angle neovascularization in proliferative diabetic retinopathy.
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Diabetic Retinopathy; Female; Fluorescein A | 2001 |
Plaque radiotherapy for choroidal hemangioma with total retinal detachment and iris neovascularization.
Topics: Brachytherapy; Choroid Neoplasms; Glaucoma, Neovascular; Hemangioma; Humans; Iodine Radioisotopes; I | 2001 |
[Dynamics of vascular changes in neovascular glaucoma. I. Development of rubeosis iridis after cryosurgery].
Topics: Cryosurgery; Glaucoma, Neovascular; Humans; Iris; Neovascularization, Pathologic | 1992 |
[Dynamics of vascular changes in neovascular glaucoma. II. Unusual findings after cryosurgery].
Topics: Cryosurgery; Glaucoma, Neovascular; Humans; Iris; Neovascularization, Pathologic | 1992 |
High incidence of sympathetic ophthalmia after contact and noncontact neodymium:YAG cyclotherapy.
Topics: Aged; Cataract Extraction; Fluorescein Angiography; Fundus Oculi; Glaucoma, Neovascular; Humans; Inc | 1992 |
The development and management of neovascular glaucoma.
Topics: Adult; Aged; Aged, 80 and over; Cell Count; Diabetic Retinopathy; Endothelium, Corneal; Female; Fluo | 1990 |
A prospective study of acute central retinal artery obstruction. The incidence of secondary ocular neovascularization.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Carotid Artery Diseases; Female; Glaucoma, Neovascula | 1991 |
A prospective evaluation of anterior retinal cryoablation in neovascular glaucoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Cryosurgery; Evaluation Studies as Topic; Female; | 1991 |
Semiconductor diode laser transscleral cyclophotocoagulation in patients with glaucoma.
Topics: Adult; Aged; Aged, 80 and over; Female; Glaucoma, Neovascular; Glaucoma, Open-Angle; Humans; Intraoc | 1992 |
The dural shunt syndrome. I. Management of glaucoma.
Topics: Aged; Anterior Chamber; Arteriovenous Fistula; Carotid Artery, Internal; Cavernous Sinus; Eye Diseas | 1990 |
Treatment of diabetic neovascular glaucoma by panretinal ablation and trabeculectomy.
Topics: Adult; Aged; Diabetic Retinopathy; Electrocoagulation; Evaluation Studies as Topic; Follow-Up Studie | 1988 |
Severe ischemic process in a young man with central retinal vein occlusion.
Topics: Adult; Atrophy; Fluorescein Angiography; Glaucoma, Neovascular; Humans; Intraocular Pressure; Iris; | 1988 |